Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
| Status: | Withdrawn |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/8/2018 |
| Start Date: | December 2010 |
| End Date: | October 2013 |
The investigators have developed imaging protocols to monitor and predict breast cancer
response to neoadjuvant chemotherapy, both prior to and as early as possible during the
course of treatment.
The efficacy and practicality of conventional imaging approaches in the neoadjuvant
chemotherapy setting varies and identifies the need for alternate functional imaging
strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that
allows patients to be followed from baseline through treatment and surgery with a
cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized
diffuse optical spectroscopic imaging technology platform that has been standardized for
neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic
research platform that is non-invasive. Studies will be performed in five clinical sites on
approximately 60 neoadjuvant chemotherapy patients.
response to neoadjuvant chemotherapy, both prior to and as early as possible during the
course of treatment.
The efficacy and practicality of conventional imaging approaches in the neoadjuvant
chemotherapy setting varies and identifies the need for alternate functional imaging
strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that
allows patients to be followed from baseline through treatment and surgery with a
cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized
diffuse optical spectroscopic imaging technology platform that has been standardized for
neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic
research platform that is non-invasive. Studies will be performed in five clinical sites on
approximately 60 neoadjuvant chemotherapy patients.
The investigators are testing the effectiveness of an experimental imaging technology known
as Diffuse Optical Spectroscopy Imaging in predicting the success of chemotherapy treatment
(shrinkage of tumor).
Diffuse optical spectroscopic imaging measurements are made with a laser breast scanner. This
bedside-capable system combines frequency-domain photon migration with steady-state tissue
spectroscopy to measure complete(broadband) near-infrared absorption and reduced scattering
spectra of breast tissue in vivo. Diffuse Optical Spectroscopy Imaging measurements are made
by placing the hand-held probe on the tissue surface and moving the probe to discrete
locations along a grid pattern at 1.0 cm intervals. The portable high-bandwidth
Frequency-Domain Photon Migration instrument employs intensity-modulated diode lasers and
conventional steady-state lamps as sources and an avalanche photodiode as the detector. The
time required to perform an Frequency-Domain Photon Migration measurement depends on the
desired precision and number of sweeps.
as Diffuse Optical Spectroscopy Imaging in predicting the success of chemotherapy treatment
(shrinkage of tumor).
Diffuse optical spectroscopic imaging measurements are made with a laser breast scanner. This
bedside-capable system combines frequency-domain photon migration with steady-state tissue
spectroscopy to measure complete(broadband) near-infrared absorption and reduced scattering
spectra of breast tissue in vivo. Diffuse Optical Spectroscopy Imaging measurements are made
by placing the hand-held probe on the tissue surface and moving the probe to discrete
locations along a grid pattern at 1.0 cm intervals. The portable high-bandwidth
Frequency-Domain Photon Migration instrument employs intensity-modulated diode lasers and
conventional steady-state lamps as sources and an avalanche photodiode as the detector. The
time required to perform an Frequency-Domain Photon Migration measurement depends on the
desired precision and number of sweeps.
Inclusion Criteria:
- Female, 18 years of age or older, non pregnant or nursing.
- Diagnosis of breast cancer and will be receiving chemo therapy treatments
Exclusion Criteria:
- 18 years of age or younger, pregnant or nursing.
- Previous treatment including chemo therapy, radiation, surgery, and hormone therapy.
- Previous diagnosis with other form of cancer.
We found this trial at
1
site
Click here to add this to my saved trials
